Sunshine Biopharma reports FY 2025 revenue $36.3M (+4.1% YoY), net loss $5.98M

Sunshine Biopharma Inc.

Revenue $36.31M vs $34.87M in 2024; gross profit $12.26M up from $10.67M.
Net loss widened to $5.98M from $5.13M, including $1.75M non-cash impairment charge.
Launched 9 new generic drugs in 2025, portfolio now 71 products; 12 more planned in 2026.
Raised $2.46M gross via registered direct offering to expand sales operations.
Cost-reduction initiatives expected to cut G&A by $2M-$3M in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sunshine Biopharma Inc. reported the year ended December 31, 2025 results: revenue $36.3 million.

Period: the year ended December 31, 2025
Revenue: $36.3 million
Result: reported results

Exact text from the filing

specific reference in such filing. --- EX-99.1 (PRESS RELEASE) --- EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE Exhibit 99.1 Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year FORT LAUDERDALE, FL / ACCESSWIRE / April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-002781

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.